Head to Head Survey: BeyondAirInc . (XAIR) & Its Competitors

Share on StockTwits

BeyondAirInc . (NASDAQ: XAIR) is one of 127 public companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare BeyondAirInc . to similar businesses based on the strength of its profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Valuation & Earnings

This table compares BeyondAirInc . and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BeyondAirInc . $7.72 million -$6.56 million -5.89
BeyondAirInc . Competitors $1.43 billion $145.31 million -15.04

BeyondAirInc .’s competitors have higher revenue and earnings than BeyondAirInc .. BeyondAirInc . is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and price targets for BeyondAirInc . and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeyondAirInc . 0 0 0 0 N/A
BeyondAirInc . Competitors 952 3184 5393 285 2.51

As a group, “Surgical & medical instruments” companies have a potential upside of 19.27%. Given BeyondAirInc .’s competitors higher possible upside, analysts clearly believe BeyondAirInc . has less favorable growth aspects than its competitors.

Volatility and Risk

BeyondAirInc . has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, BeyondAirInc .’s competitors have a beta of 1.00, meaning that their average stock price is 0% more volatile than the S&P 500.

Insider & Institutional Ownership

5.4% of BeyondAirInc . shares are owned by institutional investors. Comparatively, 51.4% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.4% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares BeyondAirInc . and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BeyondAirInc . N/A -342.71% -100.90%
BeyondAirInc . Competitors -674.05% -624.80% -22.23%

Summary

BeyondAirInc . competitors beat BeyondAirInc . on 7 of the 10 factors compared.

BeyondAirInc . Company Profile

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.

Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts’ Upgrades for September, 20th
Analysts’ Upgrades for September, 20th
Investment Analysts’ New Coverage for September, 20th
Investment Analysts’ New Coverage for September, 20th
Stock Analysts’ Downgrades for September, 20th
Stock Analysts’ Downgrades for September, 20th
Analysts’ Price Target Changes for September, 20th
Analysts’ Price Target Changes for September, 20th
Zacks Investment Research Downgrades Valvoline  to Hold
Zacks Investment Research Downgrades Valvoline to Hold
Speedway Motorsports  Rating Increased to Hold at Zacks Investment Research
Speedway Motorsports Rating Increased to Hold at Zacks Investment Research


© 2006-2019 Ticker Report